Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (226)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (639)
  2. Solid Tumor Oncology Division (639)
  3. Thoracic Oncology (639)
  4. Department of Pathology and Laboratory Medicine (210)
  5. GSK Faculty (191)
  6. Hematology-Oncology Fellows (186)

More Groups

People
  1. Marc Ladanyi (123)
  2. Mark Kris (91)
  3. Maria Arcila (83)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (23)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (85)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (119)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Response to MET inhibitors in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
    Meeting Abstract

    Paik, P.; Drilon, A.; Yu, H.; Rekhtman, N.; Borsu, L.; Ginsberg, M.; Berger, M.; Ladanyi, M.; Rudin, C. M.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for HER2 amplified or HER2 overexpressed cancers: A phase II "basket" trial
    Meeting Abstract

    Li, B. T.; Zauderer, M.; Chaft, J.; Drilon, A.; Eng, J.; Sima, C.; Makker, V.; Iyer, G.; Janjigian, Y.; Hyman, D.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Journal Article

    Plodkowski, A. J.; Drilon, A.; Halpenny, D. F.; O'Driscoll, D.; Blair, D.; Litvak, A. M.; Zheng, J.; Moskowitz, C. S.; Ginsberg, M. S.
    Lung Cancer (2015)

    Fulltext@MSK | Save
  • Patterns of RET and ROS1 FISH abnormalities seen in lung adenocarcinomas: A correlation study with targeted next-generation sequencing
    Meeting Abstract

    Wang, L.; Drilon, A.; Rao, M.; Aryeequaye, R.; Cao, L.; Islamdoust, N.; Shah, R.; Zehir, A.; Benayed, R.; Sadowska, J.; more...
    Journal of Molecular Diagnostics (2015)

    Fulltext@MSK | Save
  • Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer
    Journal Article

    Farago, A. F.; Le, L. P.; Zheng, Z.; Muzikansky, A.; Drilon, A.; Patel, M.; Bauer, T. M.; Liu, S. V.; Ou, S. H. I.; Jackman, D.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas
    Journal Article

    Eng, J.; Woo, K. M.; Sima, C. S.; Plodkowski, A.; Hellmann, M. D.; Chaft, J. E.; Kris, M. G.; Arcila, M. E.; Ladanyi, M.; Drilon, A.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements
    Meeting Abstract

    Siena, S.; Drilon, A. E.; Ou, I. S. H.; Farago, A. F.; Patel, M.; Bauer, T. M.; Hong, D.; Liu, S. V.; Lee, J.; Patel, R.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Pneumonitis with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Naidoo, J.; Cunningham, J.; Woo, K. M.; Hellmann, M. D.; Postow, M. A.; Drilon, A. E.; Chaft, J. E.; Lesokhin, A. M.; Segal, N. H.; Callahan, M. K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors
    Meeting Abstract

    Garralda, E.; Stathis, A.; Drilon, A.; Boni, V.; Hyman, D.; Calvo, E.; Griguolo, G.; Makker, V.; Doger, B.; Canziani, L.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
    Journal Article

    Davare, M. A.; Vellore, N. A.; Wagner, J. P.; Eide, C. A.; Goodman, J. R.; Drilon, A.; Deininger, M. W.; O'Hare, T.; Druker, B. J.
    Proceedings of the National Academy of Sciences of the United States of America (2015)

    Fulltext@MSK | Save